3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
76
Triple Negative Breast Neoplasms
12
Ovarian Neoplasms
7
Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms, Male
4
Pancreatic Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Melanoma
1
Interventions
pembrolizumab
13
Paclitaxel
7
Carboplatin
7
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
Gemcitabine
5
Capecitabine
5
olaparib
2
liposomal doxorubicin
2
lenvatinib
2
Doxorubicin
2
Cyclophosphamide
2
eribulin
1
efineptakin alfa
1
Vinorelbine
1
Saline Solution
1
Pemetrexed
1
Oxaliplatin
1
Glucose
1
Fluorouracil
1
Epirubicin
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
Breast
×
Clear all
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled